KR930701201A - 면역반응성 화합물 - Google Patents

면역반응성 화합물

Info

Publication number
KR930701201A
KR930701201A KR1019920703408A KR920703408A KR930701201A KR 930701201 A KR930701201 A KR 930701201A KR 1019920703408 A KR1019920703408 A KR 1019920703408A KR 920703408 A KR920703408 A KR 920703408A KR 930701201 A KR930701201 A KR 930701201A
Authority
KR
South Korea
Prior art keywords
compound according
immunoreactive
iga
igm
fragment
Prior art date
Application number
KR1019920703408A
Other languages
English (en)
Korean (ko)
Inventor
에보 시브렌 보스
페트루스 요한네스 분
Original Assignee
에프.지.엠.헤르만스.에이.지.제이.베르미렌
악조 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.지.엠.헤르만스.에이.지.제이.베르미렌, 악조 엔.브이. filed Critical 에프.지.엠.헤르만스.에이.지.제이.베르미렌
Publication of KR930701201A publication Critical patent/KR930701201A/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1019920703408A 1990-07-03 1991-06-28 면역반응성 화합물 KR930701201A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP90201781 1990-07-03
EP90201781.3 1990-07-03
PCT/EP1991/001223 WO1992000763A1 (fr) 1990-07-03 1991-06-28 Compose immunoreactif

Publications (1)

Publication Number Publication Date
KR930701201A true KR930701201A (ko) 1993-06-11

Family

ID=8205056

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920703408A KR930701201A (ko) 1990-07-03 1991-06-28 면역반응성 화합물

Country Status (7)

Country Link
EP (1) EP0537222A1 (fr)
JP (1) JPH05507924A (fr)
KR (1) KR930701201A (fr)
CA (1) CA2086531A1 (fr)
FI (1) FI925804A0 (fr)
HU (1) HUT63343A (fr)
WO (1) WO1992000763A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU556548B2 (en) * 1980-03-03 1986-11-06 Milton David Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
CA1168150A (fr) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Conjugats d'albumine et d'agents therapeutiques
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
EP0293524A1 (fr) * 1987-06-02 1988-12-07 Vasocor Immunoessai de plaque athérosclérotique
EP0295719A3 (fr) * 1987-06-19 1989-12-20 The Agouron Institute Antigène SM-D, le clonant de l'antigène SM-D et la détection de lupus érythémateux systémique en utilisant cet antigène SM-D
ATE82136T1 (de) * 1987-08-10 1992-11-15 Miles Inc Gereinigtes igm.
US4937183A (en) * 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
EP0398872A1 (fr) * 1988-02-12 1990-11-28 HighTech Receptor AB Substance de liaison d'immunoglobuline, sous-fragments, leur procede de preparation, kit de reactif et organismes de liaison d'immunoglobuline
US4983529A (en) * 1988-06-10 1991-01-08 Abbott Laboratories Immunoassay for HIV-I antigens using F(AB')2 fragments as probe
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
WO1990011091A1 (fr) * 1989-03-27 1990-10-04 Centocor, Inc. COMPOSITIONS SERVANT A STABILISER DES ANTICORPS D'IMMUNOGLOBULINE IgM

Also Published As

Publication number Publication date
HU9204170D0 (en) 1993-04-28
WO1992000763A1 (fr) 1992-01-23
JPH05507924A (ja) 1993-11-11
FI925804A (fi) 1992-12-21
EP0537222A1 (fr) 1993-04-21
CA2086531A1 (fr) 1992-01-04
FI925804A0 (fi) 1992-12-21
HUT63343A (en) 1993-08-30

Similar Documents

Publication Publication Date Title
ATE128732T1 (de) Antigenkonstrukte von ''major histocompatibility complex'' klasse i antigenen mit spezifischen trägermolekülen, ihre herstellung und verwendung.
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
EP0683234A4 (fr) ANTICORPS DIRIGE CONTRE LE -g(b)-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION.
PT752876E (pt) Anticorpos monoclonicos que se conectam com o percursor antigeneo de rejeicao de tumores mage-1, mage-1 recombinante, e peptidos imunogenicos derivados de mage-1
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
ATE294818T1 (de) Modifizierte chimäre superantigene und deren verwendung
BR0009323A (pt) Anticorpos humanos que ligam a il-12 humana e métodos para a produção
DE59309458D1 (de) Synthetische Peptide, Antikörper dagegen und ihre Verwendung
KR900013986A (ko) 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도
Atassi et al. Localization and verification by synthesis of five antigenic sites of bovine serum albumin
EP0722499A4 (fr) Antigenes immunoreactifs du virus de l'hepatite e
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
KR930701201A (ko) 면역반응성 화합물
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
Carding et al. Multiple proteins related to the soluble galactose-binding animal lectin revealed by a monoclonal anti-lectin antibody
DE69836396D1 (de) ELISA-Serodiagnose von Schweinepleuropneumonie des Serotyps 2
GB2299994A (en) Equine arteritis virus peptides antibodies and their use in a diagnostic test
Stepanik et al. Primary structure of human alpha 2-macroglobulin. III. Primary structure of three large disulfide-bridged CNBr fragments, located in the COOH-terminal part of alpha 2-macroglobulin and accounting for 301 residues.
Sanderson et al. Interchange of Allospecific MHC Class 1 Peptide Chains with Xenospecific β2Microglobulin and its Implications for Genetic Restriction
KR890010191A (ko) 만손주혈흡충에 대한 백신
GB2333295A (en) Modified protein G and fragments thereof

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid